BioLabs

What a moment! Yesterday, July 15, 2025, we joined Berlin Institute of Health (BIH) to celebrate the Grand Opening of the Clinical Incubator (CLIC), a de-risking launchpad connecting startups and academic projects with clinicians, patients, regulators, and Europe’s top translational network.   We’re proud to support BIH’s vision, bridging Berlin’s research excellence with global entrepreneurial impact.   Before the ribbon cutting, we heard from key leaders: 💭 "This is where innovation meets technology to convert ideas into impact and turn research into help." — Prof. Dr. Christopher Baum, BIH / Charité 🎙️ "Great science doesn’t have to stop at the bench. It can go all the way to the bedside." — Johannes Fruehauf, BioLabs   We also hosted the panel “From Founding to Funding”, featuring voices from BIH, BioLabs, Bayer, Nucleate, and Charité - Universitätsmedizin Berlin. Together, they shared what it takes to move science from discovery to patient-ready solutions, through mindset, funding, and collaboration.   To Berlin Institute of Health, Charité - Universitätsmedizin Berliné, Bayer, Max Delbrück Center, and all our ecosystem partners: thank you for making this vision a reality.   To every scientist or founder ready for the next step — 🇩🇪 Berlin is building the bridge. We’re ready when you are. Johannes Fruehauf | Prof. Dr. Christopher Baum | Johanna Michielin | Garima Bhardwaj, Ph.D. | Clément Lapierre | Franka Klatte-Schulz | Ann-Kristin Mueller | Marion Hitchcock | Univ.-Prof. Dr. Ing. Georg Duda | Philip Hemme | Hannah Payette Peterson

🚨 Calling all life science innovators in Japan! 🚨 Applications are now open for the AbbVie Japan Innovation Award 2025. If you're a Japanese startup developing breakthrough science with potential global impact, this is your opportunity to supercharge your journey. 📅 Deadline: August 15, 2025 🔗 Apply now: https://lnkd.in/ePQYiPnr AbbVie, Biolabs@NYULangone, BioLabs North Carolina, BioLabs New Haven, BioLabs Pegasus Park - North Texas, BioLabs Innovation Center at University of Vermont, BioLabs San Diego, BioLabs at The Lundquist Institute, BioLabs for Advanced Therapeutics Philadelphia, BioLabs Greater Boston, Princeton Innovation Center BioLabs, BioLabs France, BioLabs Heidelberg, Christian R. Schubert, Christina Vorvis, PhD, Yusuke Throndson, Mission BioCapital

🌍 Global Go-To-Market Planning: US, EU & MENA Perspectives  📅 July 29, 2025 | 🕘 4:00–5:00 PM AST / 9:00–10:00 AM EDT  📍  Zoom Webinar 🔗 Register now: https://lnkd.in/g4PEKS3U 🚀 Ready to take your biotech startup global? Join us for an action-packed webinar hosted by BioLabs in partnership with the Ministry of Health Saudi Arabia as part of the MOH Accelerator Program! Discover how to successfully expand into the US, EU, and MENA markets with expert insights on regulatory strategy, commercialization models, and real-world case studies that will help you avoid costly missteps. 🎤 Speaker: Maria Lamottke Whether you’re scaling internationally for the first time or refining your growth strategy, this session is your roadmap to success. Don’t miss out! #BioLabs #biotech #startups #MOHAccelerator #globalexpansion #lifesciences #businessdevelopment #webinar #biotechstrategy #internationalgrowth

🎧 Innovation Can’t Wait: New b.empowered Podcast Episodes Out Now!🎧 In our latest conversations during BioLabs' b.empowered video Series recorded at BIO2025, we’re spotlighting two resident companies that are racing to bring meaningful change to patients through bold science and rapid innovation. 🔹 Vincere Biosciences Based at BioLabs Greater Boston, Vincere Biosciences is tackling neurodegenerative diseases. In this episode, Andy Lee, Vincere Bio's co-founder & CBO and Johanna Michielin from BioLabs explore how Vincere Biosciences is working to move faster in a field that can’t afford delays. 🎙 Listen here: https://lnkd.in/eCkC4Tgn 🔹 BIMOVIS This BioLabs Heidelberg based startup is rethinking how data and modeling can power faster, more precise diagnostics and therapies. Markus Krohn CTO of BIMOVIS and Johanna Michielin from BioLabs talk about the role of AI, international collaboration, and why early innovation must happen without hesitation. 🎙 Listen here: https://lnkd.in/esSFnPsW These episodes are part of BioLabs' b.empowered video series exploring what it takes to move science forward—urgently, responsibly, and with lasting impact. 👉 To access all episodes visit: https://lnkd.in/e4ZCQffq. Tune in and let us know what resonates.

🤝 BioLabs AND Sartorius RENEW AND EXPAND PARTNERSHIP🤝 We’re thrilled to announce the renewal and expansion of our US Network sponsorship with Sartorius! Over the past few years, our collaboration with Sartorius has been instrumental in supporting early-stage biotech companies and empowering innovators across the BioLabs network. As BioLabs has expanded into new geographies, this partnership has grown with us, reaching more entrepreneurs and enabling greater impact across BioLabs' growing network. We’re excited to continue building on this strong foundation and look forward to another impactful chapter together. Thank you to the Sartorius team for your continued trust and support—we’re proud to have you as part of the BioLabs community! Remi Laliberte, Hayley Smith, David Kent, BioLabs Greater Boston, BioLabs San Diego, BioLabs North Carolina, BioLabs at The Lundquist Institute, BioLabs New Haven, BioLabs Pegasus Park - North Texas, Princeton Innovation Center BioLabs, Biolabs@NYULangone

🎧 New Podcast Episodes – Now Live! As part of our “Innovation Can’t Wait” series at BIO 2025, we’re featuring conversations with two organizations who are helping life science innovators move faster, smarter, and more resiliently. 🔹 Elemental Machines- A BioLabs Network Sponsor From lab sensors to smart data infrastructure, Elemental Machines is transforming how labs operate—so scientists can focus on discovery, not disruption. In this episode, Melina Blees, from BioLabs for Advanced Therapeutics Philadelphia and Sridhar Iyengar from Elemental Machines dive into how automation and real-time insights are removing bottlenecks at the bench and fueling innovation at scale. 🎙 Listen here: https://lnkd.in/e8hziNsR 🔹 Conner Strong & Buckelew Innovation moves fast, but risk doesn’t wait. Gabby Everett from BioLabs Pegasus Park - North Texas and Brad Watts from Conner Strong & Buckelew spoke about how smart risk strategy and benefits planning enable healthcare and life sciences organizations to grow with confidence and make a bigger impact—without slowing down. 🎙 Listen here: https://lnkd.in/e_kigE7A

🥁 Announcing the Four Finalists for the 2025 Ipsen #GoldenTicket We are proud to unveil the four startups selected as finalists for the 2025 Ipsen Golden Ticket, a program offering one year of free lab and office space at BioLabs Hôtel-Dieu, right in the heart of Paris. Each finalist embodies scientific excellence and bold ambition, tackling some of the most urgent challenges in human health: 🧬 StarkAge Therapeutics Senescent cells build up in tissues as we age, contributing to cancer, fibrosis, and other chronic diseases. StarkAge is developing antibody-drug conjugates that selectively eliminate these cells. Their approach could change how we treat cancer and age-related disease at its root. 🧪 DETERA Therapeutics People with crescentic glomerulonephritis often end up on dialysis within months of diagnosis. Detera is working on an innovative peptide therapy that acts earlier, protecting kidney function before damage becomes irreversible. It’s a new way of thinking about intervention in rare kidney disease. 💊 InFocus Therapeutics RNA splicing errors drive many cancers and neurological diseases, but drugging them has been a major challenge. InFocus is building orally available small molecules that target these errors with precision. Their work could finally make RNA splicing a practical target in the clinic. 🧠 CLOVERNA Most discovery platforms overlook non-coding RNA, even though that’s where most disease-linked mutations occur. CLOVERNA’s platform identifies functional non-coding RNA targets directly in disease models. Their lead program targets TDP-43 aggregation in ALS, seen in the majority of patients. 🙏 Thanks to the jury members for their thoughtful involvement Emily Fang | Lyse Santoro | Benjamin LeCalvé | Tatsuo Ito | Catherine George | Florence Dal Degan | Benjamin Boiseau | Mehdi ZOUAOUI

🎟️ Golden Ticket Season is Here — Around the World! 🌍 At BioLabs, we’re proud to support innovation globally by partnering with industry leaders to offer Golden Ticket programs—These programs are more than just awards—they're a launchpad. Winners gain lab bench access, mentoring, strategic connections, and visibility in one of the world’s most vibrant innovation networks. Here’s a look at some of the exciting programs currently running across our network: 🇯🇵 Japan — In collaboration with AbbVie Japan, this award offers access to BioLabs and ¥10 million in funding for breakthrough Japanese biotech startups. 🇺🇸 United States — Multiple Golden Tickets are currently open across our U.S. locations with partners like Otsuka (US Network Golden Ticket) and Amgen (LA based Golden ticket) giving startups access to lab space and connections with world-class pharma leaders. 💡 Know a startup that should apply? 📩 Visit our website to learn more and to apply: https://lnkd.in/eb9Sy-CQ

🎙 New b.empowered Podcast Episodes Are Live! In our latest series during BIO 2025, exploring the theme “Innovation Can’t Wait,” we sat down with two groundbreaking BioLabs resident companies that are accelerating innovation in areas where urgency matters most. 🔹 Ten63 Therapeutics - Based in North Carolina, Ten63 is harnessing the power of AI and physics to dramatically speed up drug discovery. John Freeman CPA, MST, CGMA and Marcel Frenkel, PhD talked about how Ten63 Therapeutics' approach is reducing timelines and pushing the boundaries of what’s possible in drug discovery and patient care. 🎧 Listen here: https://lnkd.in/eDCYZsxx 🔹 ReST THERAPEUTICS- A Current resident at BioLabs New Haven. With a focus on brain health and trauma, ReST Therapeutics is developing targeted therapies for conditions like PTSD and Alzheimer’s. In this conversation, Johanna Michielin and Anthony R. Franco discussed why the world can’t wait for better mental health treatments—and how ReST THERAPEUTICS is working to deliver them faster. 🎧 Listen here: https://lnkd.in/efsC8X7f 👇 Listen to all our b.empowered podcasts recorded live from our booth at BIO2025, share, and let us know what you think innovation needs next. https://lnkd.in/e4ZCQffq BioLabs North Carolina, BioLabs New Haven

🚀 Exciting Opportunity for Early-Stage Startups in the US! We’re thrilled to announce the launch of Otsuka Pharmaceutical Co., Ltd.'s US network Golden Ticket campaign. A unique chance to win a free lab bench at any BioLabs location in the U.S. In partnership with Otsuka Pharmaceutical Co., Ltd. Pharmaceutical, this opportunity not only provides physical space to grow your biotech venture—but also the chance to build meaningful connections with industry leaders at Otsuka. 🌟 If you’re an innovative early-stage life science company ready to take the next step, this is for you. 👉 to learn more about eligibility and to apply visit: https://lnkd.in/ewfMMh_K BioLabs Greater Boston, BioLabs New Haven, Biolabs@NYULangone, BioLabs for Advanced Therapeutics Philadelphia, Princeton Innovation Center BioLabs, BioLabs Innovation Center at University of Vermont, BioLabs Pegasus Park - North Texas, BioLabs San Diego, BioLabs North Carolina, BioLabs at The Lundquist Institute